Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020112149 - PROCÉDÉS ET COMPOSITIONS POUR L'ÉVALUATION D'UN INFARCTUS DU MYOCARDE AIGU (AMI)

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

This study identified Cer(18: 1 /18:0), Cer(18: 1 /16:0), Cer(18: 1/24:1 ),

Cer(18:1/18:0)/24:0, Cer(18:1/16:0)/24:0, Cer(18: 1/24:1 )/24:0 as differential biomarkers for AMI.

Claims

What is claimed is:

1. A method comprising:

measuring the concentration of 1 to 6 metabolite species in a sample of a bio-fluid from a subject to be tested for AMI, wherein the 1 to 6 metabolite species is a component of a panel of a plurality of metabolite species, wherein a change in the concentration of the metabolite species is a characteristic that is associated with AMI, which providing an AMI marker level representation for a subject, the method comprising: evaluating a panel of AMI markers in a blood sample from a subject to determine the level of each AMI marker in the blood sample; and obtaining the AMI marker level representation based on the level of each AMI marker in the panel, wherein the panel of AMI markers comprise Ceramide(Cer).

2. The method according to claim 1 , wherein the panel of AMI markers further comprise one or more AMI markers or their ratios selected from the group consisting of

Cer(18:1/18:0), Cer(18: 1 /16:0), Cer(18: 1/24:1 ), Cer(18:1/18:0)/24:0,

Cer(18:1/16:0)/24:0, and Cer(18:1/24:1 )/24:0

3. The method according to claim 1 , wherein the panel of AMI markers comprises metabolite species that have been identified by liquid chromatography-mass

spectrometry (LC-MS): Cer(18:1/18:0), Cer(18:1/16:0), Cer(18:1/24:1 ),

Cer(18:1/18:0)/24:0, Cer(18:1/16:0)/24:0, and Cer(18:1/24:1 )/24:0.

4. The method according to claim 2, wherein the panel of AMI markers comprises of

Cer(18:1/18:0), and Cer(18:1/18:0)/24:0.

5. The method of claim 1 , wherein the bio-fluid is selected from the group consisting of

blood, plasma, serum, sweat, saliva, sputum, and urine.

6. The method of claim 1 , wherein the bio-fluid is serum.

7. A panel of metabolite species, the metabolite species are selected from a group

consisting of Cer(18: 1/18:0), Cer(18:1/16:0), Cer(18: 1/24:1 ), Cer(18:1/18:0)/24:0,

Cer(18:1/16:0)/24:0, and Cer(18:1/24:1 )/24:0.

8. The panel of claim 7, wherein the panel is provided in a diagnostic cassette.

9. The diagnostic cassette of claim 8, further comprising reagents for the detection of

the metabolite species of the panel.

10. A kit for the analysis of a sample of a biofluid of a subject, comprising:

a. Aliquots of standards of each compound of a panel of metabolite species;

b. An aliquot of an internal standard; and

c. An aliquot of a control biofluid.

11. The kit of claim 10, wherein the control biofluid is serum from a control source that is

conspecific with the subject.

12. The kit of claim 11 , wherein the panel consists of D7-d18:1 -16:0 Ceramide, D7-d18: 1 -18:0 Ceramide, D7-d18: 1 -24:0 Ceramide, D7- d18: 1 -24:1 Ceramide 13. The kit of claim 10, further comprising instructions for use.